# Syschem (India) (NSE: SYSCHEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SYSCHEM · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹214 Cr, it ranks 2233rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Promoters held 63.38% of the company as of 14 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹214 Cr |

## Shareholding (14 Jul 2026)

- Promoters: 63.38%
- Domestic institutions: 0.15%
- Non-institutions: 36.47%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Nectar Lifesciences](https://app.pivotnow.in/stock/NECLIFE) | ₹11.34 | ₹220 Cr | 100 | −50.3% |
| [Hannah Joseph](https://app.pivotnow.in/stock/HANNAH) | — | ₹220 Cr | — | 13.9% |
| [Achyut Health](https://app.pivotnow.in/stock/ACHYUT) | — | ₹209 Cr | 100 | 1.7% |
| [Coral Labs](https://app.pivotnow.in/stock/CORALAB) | — | ₹196 Cr | 10 | 12.0% |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | 50 | 3.2% |
| [Brooks Laboratories](https://app.pivotnow.in/stock/BROOKS) | ₹63.12 | ₹186 Cr | 7.6 | −10.2% |

## Questions and answers

### What is the market cap of Syschem (India)?

Syschem (India)'s market capitalisation is ₹214 Cr (₹214 Cr) at the 22 Oct 2026 close, ranking 2233rd among the NSE companies Pivot tracks.

### What is the shareholding pattern of Syschem (India)?

As of 14 Jul 2026: promoters 63.38%, domestic institutions 0.15%, non-institutions 36.47%.

### Who are Syschem (India)'s competitors?

The listed Pharma & Healthcare companies closest to Syschem (India) by market cap are Nectar Lifesciences, Hannah Joseph, Achyut Health, Coral Labs, Aashka Hospital and Brooks Laboratories.

### Is Syschem (India) a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Syschem (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SYSCHEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.